Objective: To make evidence-based recommendations for screening, diagnosing, and treating psychiatric disorders in individuals with multiple sclerosis (MS).
Individuals with multiple sclerosis (MS) are at increased risk of emotional disorders. With effective treatments widely available for several emotional disorders, this component of the burden of MS can be reduced. 1, 2 Undetected and untreated mental illness may worsen functioning 3 and quality of life, [4] [5] [6] [7] [8] decrease treatment adherence, 9 and increase risk of suicide. [10] [11] [12] [13] [14] [15] [16] Improved detection, diagnosis, and treatment practices in medical settings where individuals with emotional disorders are often first seen would help ameliorate these negative outcomes. This guideline reviews the evidence and makes recommendations for identifying, diagnosing, and treating psychiatric disorders in individuals with MS.
Among individuals with MS, relative to the general population, lifetime prevalence rates are elevated for major depressive disorder (MDD) (36%-54% vs 16 .2%), [17] [18] [19] [20] [21] [22] [23] bipolar disorder (13% vs 1%-4.5%), 20, 24, 25 anxiety disorders (35.7% vs 28.8%), 26, 27 adjustment disorders (22% vs 0.2%-2.3%), [28] [29] [30] and psychotic disorders (2%-3% vs 1.8%). 31 Suicide may be at least twice as common. [10] [11] [12] [13] [14] [15] [16] Prevalence estimates for pseudobulbar affect (PBA) range from 6.5% to 46.2% [32] [33] [34] ; the prevalence of euphoria is unknown. 35 Depressive and manic/hypomanic symptoms may occur with high-dose corticosteroids, 36 but the association between depressed mood and disease-modifying therapies is unclear. 37 We use the accepted term emotional disorders to signify both disturbances of mood (persistent inner emotional states) and disturbances of affect (changing external expression of emotions). 38 In MS, affect disturbances (e.g., PBA, euphoria, apathy) may result from the pathologic process, whereas mood disturbances (e.g., depressed mood, anxiety) have a multifactorial etiology: MS-related processes, genetic and environment-related predispositions, normal grieving, and adjustment to loss. Disorders of mood and affect may coexist.
We also distinguish symptoms from diagnosable disorders and screening from diagnostic instruments. Symptoms (e.g., depressed mood, anxiety) are reported spontaneously by individuals or elicited through interviews, questionnaires, checklists, and severity rating scales. 39,40,e1-e11 Emotional disorders (e.g., major depressive, dysthymic, bipolar, anxiety, adjustment) are diagnosed according to criteria 38,e12 that stipulate the number and types of symptoms and their duration, intensity, and impact on functioning. Clinicians collect diagnostic information with unstructured, open-ended interviews; researchers use structured e13-e16 and semistructured 39,e17 interviews. Table 1 lists instruments mentioned in the Class I2III studies cited below; we accepted at face value the instruments used as reference standards. The project development plan had 9 clinical questions. We found evidence to support recommendations for the 3 below; the remaining 6 are listed later in this article. One Class II study e18 evaluated the Center for Neurologic Study Emotional Lability Scale (CNS-LS) as a screening tool for PBA. The CNS-LS is a 7-item selfreport questionnaire that rates the frequency of episodes of pathologic laughing (4 items) and crying (3 items) on a 5-point scale; higher scores indicate greater frequency. Investigators recruited from 7 communitybased general neurology referral centers 90 individuals with MS with or without PBA diagnosed by physicians who conducted clinical interviews. They administered the CNS-LS, used receiver operating characteristic analysis to identify a cut-point of 17 or greater, and found 94% sensitivity, 83% specificity, 87% positive predictive value (PPV), and 92% negative predictive value (NPV). Physician diagnoses were not systematically linked to detailed clinical assessments, however, and the recruitment strategy may have oversampled individuals with more severe PBA.
Another Class II study e20 examined the ability of the General Health Questionnaire (GHQ) e4 to detect broadly defined "emotional disturbances" classified using the Present State Examination e16 as the reference standard. Investigators used a convenience sample of primarily newly diagnosed individuals. Emotional disturbance was common (13/25 subjects), and the GHQ had high sensitivity and specificity (92% each).
A third Class II study 28 investigated performance of the original Beck Depression Inventory (BDI) 40,e1 relative to diagnostic assignment of MDD by the Diagnostic Interview Schedule. e14 Investigators used a consecutive series of 46 newly diagnosed individuals at an MS clinic and calculated sensitivity, specificity, PPV, and NPV for BDI scores from 9 to 21. Scores from 0 to 9 are usually considered normal, scores over 17 are strongly associated with depressive disorders, and scores from 10 to 17 generally indicate dysphoria but may include other diagnosable depressive disorders. e30 A cut-point of 13 produced 71% sensitivity, 79% specificity, 70% PPV, and 79% NPV. Although this study showed that the original BDI can detect MDD in individuals with MS, a cut-point of 13 leaves nearly 30% of cases undetected. Cut-points low enough to preserve sensitivity produced a substantial number of false-positive ratings. As specificity was calculated with reference to MDD, some individuals with false-positive ratings may have had adjustment disorders. Because the cut-point was identified in the same test sample, these estimates require replication in an independent sample.
A fourth Class II study e19 examined performance of a 2-question screening tool developed for use in primary care settings e31 relative to diagnoses assigned by the Structured Clinical Interview for the DSM-IV (SCID-IV). 38 One question asked about depressed mood, the other about diminished interest or pleasure; an affirmative response to either question produced a positive screen. Investigators recruited 260 volunteers from among 502 individuals with MS in a Northern California Kaiser Permanente Medical Care Group database. As expected, because a DSM-IV diagnosis requires either depressed mood or diminished interest or pleasure, the screen identified 66 of the 67 individuals (98.5%) with MDD. Specificity was lower (87%). Investigators observed that among the 13% with false-positive scores, more than half actually had subthreshold depressive disorders; detecting these disorders may have clinical utility. With a 26% observed point prevalence, sensitivity and specificity translated into 72% PPV and 99% NPV, respectively. Self-selection bias and a low response rate may have affected study results. One Class III study e24 examined the ability of a 1-question screen ("Are you depressed?") to detect MDD. This method produced a high false-negative rate: 30% of subjects who responded "no" were found to have a depressed mood. The study lacked an acceptable validation standard.
A second Class III study e21 investigated potential confounding effects of somatic symptom items on BDI ratings. The investigators compared the proportional contribution of each of the 21 items in the original BDI 40 with total scores across 3 groups: individuals with MS, individuals with Diagnostic Interview Schedule-diagnosed MDD, and college students. The proportional contributions of work problems, fatigue, and health concerns were greater in individuals with MS than in the other groups.
A third Class III study e23 used correlation analysis and structural equation modeling to examine relationships between neurovegetative symptoms assessed by the original BDI 40 (sleep disturbance, fatigue, appetite change, decision-making difficulty, loss of libido) and measures of depressed mood (Chicago Multiscale Depression Inventory), e6 fatigue, and disability in 76 individuals with MS. Four of the 5 neurovegetative symptoms correlated with depressed mood and fatigue (p , 0.01); none correlated with disability.
The last Class III study e22 determined PPV in a series of MS clinic patients screened for Center for Epidemiologic Studies Depression Rating Scale (CES-D) scores $16.
e2 Because all subjects scored $16, NPV could not be calculated. PPV was calculated as the proportion of subjects with a CES-D score .16 and diagnosed with a mood disorder in a subsequent clinical interview. The estimates were consistent with those reported elsewhere: 60% PPV for subjects with MDD and 75% for those with major depressive or dysthymic disorder. Diagnoses were not based on a validated diagnostic interview.
Conclusions and recommendations. In individuals with MS, the CNS-LS is possibly effective and may be considered for screening for PBA (Level C, 1 Class II study e18 ). The GHQ e4 is possibly effective and may be considered for identifying individuals with broadly defined emotional disturbances (Level C, 1 Class II study e20 ). The BDI 40 and a 2-question screen e31 are possibly effective and may be considered for identifying individuals with MDD (Level C, 1 Class II study each 28,e19 ). There is insufficient evidence to support/refute using the CES-D e2 to screen for depressive symptoms e22 or a single question to screen for MDD e24 (Level U, 1 Class III study each); the possibility that somatic or neurovegetative symptoms negatively affect the accuracy of BDI results (Level U, 2 conflicting Class III studies) e21,e23 ; and the use of specific instruments or clinical evaluation procedures to diagnose emotional disorders in individuals with MS (Level U).
Clinical context. Because emotional disorders may be unrecognized in medical settings, validated screening tools might improve identification of individuals who could benefit from further evaluation and treatment. The true positive rate of a screening tool depends not only on its sensitivity but also on the point prevalence of the disorder in the population under study. Clinically, false-positive results are not a major concern because individuals with the conditions typically identified (e.g., adjustment and subthreshold depressive disorders) can benefit from further assessment. Administratively, however, screening tools with high falsepositive rates unnecessarily increase resource use. The Class II study, e33 a randomized controlled trial, compared a systematic 16-week telephone-administered cognitive behavioral therapy (CBT) program (T-CBT) for treating individuals with MS who had clinically significant depressive symptoms e47,e48 with a validated telephone-administered supportive emotionfocused therapy (T-SEFT) e49 to control for nonspecific effects of T-CBT. Enrolled subjects had scores $14 on the Hamilton Depression Rating Scale (HDRS) e11 and scores $16 on the BDI-II.
e1 During treatment, subjects in both arms showed significant improvement. After treatment, the T-CBT group showed significantly greater reductions in diagnoses of MDD (SCID-IV) and depressive symptoms (HDRS) relative to the T-SEFT group (13.3% vs 29.0%, d 5 0.42, p 5 0.02). In contrast to the clinician-administered measures (HDRS, SCID-IV), however, self-
T-CBT relative to T-SEFT, but no significant differences between T-CBT and T-SEFT in depressive symptoms (BDI-II). After 1 year, treatment gains were sustained for both T-CBT and T-SEFT-there was no significant worsening on any measure-but differences between treatments were no longer significant.
An earlier randomized controlled evaluation (Class  III) e37 examined the effects of T-CBT e47,e48 among individuals with MS with at least moderate baseline levels of depressive symptoms on the Profile of Mood States (POMS) depression scale.
e9 Subjects who received T-CBT had significantly greater improvement in POMS scores than usual care controls (d 5 0.97, p 5 0.01).
Another randomized, controlled, nonpharmacologic study (Class III) e34 compared 6-session, CBTbased "stress inoculation training" (CBT plus relaxation training) with 2 hours of supportive psychotherapy. A comparative treatment effectiveness study (Class  III) e36 compared 16 weeks of in-person individual CBT, e47,e48 supportive emotion-focused group therapy (SEGT), e50 and sertraline for treating individuals diagnosed at baseline with MDD (SCID-IV). 39 Significant improvements in depressive symptoms on the BDI and HDRS were obtained for CBT and sertraline (mean doses, 88.75 mg/d for all participants, 139 mg/d for completers) but not for SEGT. Relative to SEGT, both CBT (d 5 0.58, p 5 0.003) and sertraline (d 5 0.46, p 5 0.047) produced significantly greater improvements; there were no statistical differences between CBT and sertraline. Treatment gains were maintained at 6-month follow-up for CBT and sertraline. SEGT was significantly less effective than either CBT or sertraline posttreatment. There was no difference in efficacy between CBT and sertraline.
A randomized controlled study (Class III) e38 compared a 6-session group treatment involving relaxation and imagery (of positive immune function and myelin repair) with a no-treatment control. Enrolled subjects showed significantly elevated baseline anxiety levels on one outcome measure, the STAI, e10 but not on another, the POMS.
e9 Subjects in the relaxation and imagery group showed significant posttreatment reductions in anxiety on the STAI relative to controls (d 5 0.82, p , 0.05). Given the lack of elevated baseline anxiety levels on the POMS, it is unclear whether these results can be generalized.
A controlled but nonrandomized Class III study e35 comparing 5 weeks of desipramine (mean dose, 136 mg/d) plus psychotherapy with placebo plus psychotherapy produced inconsistent findings: significant change on the HDRS but not on the BDI. Several issues limit interpretation of the findings, including nonrandomization of subjects and small sample size (n 5 28).
A randomized, double-blind, placebo-controlled trial e39 comparing paroxetine 20 mg/d with placebo for 12 weeks found no differences between them on the primary outcome measures of $50% decrease in depressive symptoms and number of subjects scoring #7 on the HDRS. e11 Because the study was underpowered, its results are difficult to interpret. We rated the study Class III because the treatment groups' baseline characteristics were not described, the samples were small, and 23% of subjects withdrew.
A single-blind, randomized, Class III study e40 looked at the effects of CBT-based group therapy (6 sessions over 12 weeks) in 20 individuals with MS with a score on the Hospital Anxiety and Depression Scale e51 .7 or .2 on the GHQ e4 at treatment onset. Treated subjects had fewer depressive symptoms (p , 0.05) than a matched control group (n 5 20) assigned to a waiting list. Results were nonsignificant when corrected for multiple outcomes, and there were no significant differences in anxiety. or CBT-based group therapy e40 for depressive symptoms; or 2) individual in-person CBT plus relaxation training, e34 group relaxation and imagery, e38 or CBTbased group therapy e40 for anxiety (Level U, 1 Class III study each).
Clinical context. There is evidence supporting the efficacy of pharmacologic and nonpharmacologic therapies for depressed mood and anxiety in individuals without MS. Despite the lack of evidence in individuals with MS, these therapies are frequently used to treat emotional disorders in this population.
Question. What are the effective treatments for disorders of affect in individuals with MS?
Analysis. One Class II study e52 addressed this question for PBA in a randomized controlled trial comparing dextromethorphan and quinidine (DM/Q) with placebo. Investigators measured presence and severity of PBA with the CNS-LS e18 and determined the adjusted mean change in CNS-LS score at 4 assessments over 12 weeks. Secondary outcomes included the number of episodes of laughing or crying, or both, between visits and the proportions of subjects with complete symptom remission and at least a 3-point decrease in mean CNS-LS score. Investigators also used a pain rating scale and measured quality of life and relationships with visual analog scales. Treated subjects had significantly greater reductions in mean CNS-LS scores at all 4 assessments, and significantly more treated subjects showed a 3-point or greater mean score decrease (83.6% treated vs 49.3% untreated; p , 0.0001, risk difference 34%, 95% confidence interval 21%-48%). Treated subjects also improved significantly on all secondary outcome measures. Dizziness was the only adverse event that occurred more frequently in the treated (26.3%) vs placebo (9.5%) group, and only one treated subject rated it as severe. This study is Class II because of dropout rates (27.6% treated, 28.4% placebo).
Conclusion and recommendations. DM/Q is possibly effective and safe and may be considered for treating individuals with MS with PBA (Level C, 1 Class II study).
e52
Clinical context. DM/Q is the only drug approved by the US Food and Drug Administration for PBA treatment, although other drugs are used in clinical practice (e.g., selective serotonin reuptake inhibitors, tricyclic antidepressants). There are no randomized placebo-controlled trials of these other agents.
RECOMMENDATIONS FOR FUTURE RESEARCH
Despite advances in clinicians' recognition that emotional disorders are common among individuals with MS, these disorders are often undetected and inadequately treated.
e53-e55 Research is limited, and there are few Class I studies to guide recommendations. Below are examples of studies that could provide evidence to improve detection, diagnosis, and treatment practices.
Screening and diagnosis.
• Head-to-head comparisons of screening tools and diagnostic instruments to determine which best identify particular emotional symptoms (e.g., depressed mood, anxiety) and emotional disorders (e.g., MDD, adjustment disorder) • Evaluations of methods to train MS clinicians to identify emotional disorders, educate individuals with MS and family members to recognize emotional symptoms, and encourage open discussion of these problems • Comprehensive evaluations of screening initiatives including feasibility, cost, use of results, and outcomes • Comparisons of methods to distinguish, in an individual, sources of somatic and neurovegetative symptoms that could be attributed to both an emotional disorder and MS
• Assessments of instruments to screen for and diagnose euphoria, apathy, and emotional dysregulation • Appraisals of standard screening and diagnostic instruments to identify and determine the prevalence of other psychiatric disorders among individuals with MS Treatment.
• Large, methodologically rigorous, randomized, placebo-controlled studies to evaluate nonpharmacologic and pharmacologic therapies with strong evidence of efficacy and widespread use for treating emotional disorders in individuals without MS. Examples include the following: ∘ Double-blind comparative-effectiveness trials of frequently used antidepressants with attention to their impact on outcomes of different types of emotional symptoms and disorders, MS impairments (e.g., physical, cognitive), and concurrent MS treatments ∘ Targeted comparative-effectiveness trials for frequently used types of nonpharmacologic interventions (e.g., CBT, psychotherapy) and different approaches (e. We included these questions at the outset because they are clinically relevant: individuals with MS may have psychotic disorders and require treatment. Clinicians may have difficulty determining whether fatigue, for example, is due to MS or depressed mood and therefore selecting appropriate treatment. Individuals with MS may experience emotional symptoms while taking disease-modifying therapies, corticosteroids, and symptomatic agents, and may become suicidal. We reviewed studies on these issues, but none met criteria to support recommendations. Neurologists, individuals with MS, and families would welcome well-designed investigations of the effects of interferons on mood. They would also benefit from knowing whether particular characteristics of individuals with MS might predict suicide.
• Cognitive and emotional disorders co-occur, and it can be difficult to determine the source of inattention, distractibility, slowed thought processing, and difficulty concentrating. Further research is needed on screening, diagnosing, and distinguishing these disorders and on effective treatments when they co-occur.
• We reviewed only studies of adults with MS.
Future research should address emotional disorders in children and adolescents with MS, including comparisons with adults with MS and children and adolescents without MS.
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